RE:SPCEO1 & WINOYou are right, there is not much else to say at this point. THTX has to deliver on sales and cost cutting and all will be kinda, sorta alright if they do. I personally consider NASH to be a non-starter but might be surprised on that front. As I have said, I will believe it when I see it. If TH-1902 gets past the scientific advisory committee and the revised protocol is something the FDA approves, then things could potentially get a lot better real quick in early 2024, which would be just in time as well given the uncertain situation regarding whether the F8 will be approved by 3/24 and the negative financial impact it would have if it didnt. If they have good data from TH-1902 by then, they could raise the needed funds pretty easily to get well beyond $30 million in cash. They might get to $30 million in cash even without that if they manage the drug sales and costs well. Additionally, while they will not get the F8 approved by 12/31/23, which means they have to start paying the principal portion of the Marathon loan back in July or August of 2024 rather than July/August 2025, they may be in good enough financial shape at that point to refinance the loan on better terms. I don't think they will even take down tranche 3 of the loan.
Basically, the stock is much too cheap if that scenario plays out and I think it has a good chance of doing so.
PWIB123 wrote: Gentlemen, you've been mostly silent here lately, and I don't blame you. I'm not sure there's much to add until we see how things play out. I feel trapped and would love to hear your thoughts if you have any on the current state of affairs.